New medicine that spur weight loss and treat diabetes have been having the public—as well as pharmaceutical industry—by storm. The latest entrant, Zepbound, a short while ago joined Ozempic, Wegovy, Victoza and others in a escalating course of medications termed GLP-one receptor agonists.Possessing this condition in the past may possibly raise